TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23128768

Group type: EXPERIMENTAL
Intervention: Soothe/Sleep intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Introduction of Solids intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: No interventions
Number of subjects: 0
Study: 20506674

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg per day from day 3 to day 7 of the cycle
Number of subjects: 19

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg per day on the same cycle days
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Letrozole
Number of subjects: 19
Study: 17109725

Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA) with protein A; N = 5
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no immunoadsorption); N = 5
Number of subjects: 10
Study: 15640336

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg b.i.d. for 2 weeks
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) in nonsmokers
Number of subjects: 135
Study: 11966868

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with lansoprazole 30 mg b.i.d. for 7 days (group LAT)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d. plus tetracycline 500 mg q.i.d. with ranitidine bismuth citrate 400 mg b.i.d. for 7 days (group RBCAT)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Amoxicillin 1 g b.i.d. plus doxycycline 100 mg b.i.d. and lansoprazole 30 mg b.i.d. for 14 days (group LAD)
Number of subjects: 270
Study: 9918267

Group type: EXPERIMENTAL
Intervention: Generic quality of life measures (NHP and RAQOL)
Number of subjects: 40
Study: 7772357

Group type: EXPERIMENTAL
Intervention: Succinylcholine (S) 1 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rocuronium (R) 600 mcg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rocuronium (R) 150 mcg/kg (open label)
Number of subjects: 24
Study: 2278610

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 341951

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg four times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin (500 mg four times daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin with sulphametopyrazine (1 g at start of exacerbation followed by erythromycin 500 mg four times daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ampicillin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin plus sulphametopyrazine
Number of subjects: 0
Study: 30466880

Group type: EXPERIMENTAL
Intervention: Randomization tests on micro-level data
Number of subjects: 0
Study: 28792952

Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/day (after crossover from placebo)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 112
Study: 26680412

Group type: EXPERIMENTAL
Intervention: Unloader brace
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 18
Study: 22725971

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (1-hour sessions, totaling 36 sessions over 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Eutrophic group (EG)
Number of subjects: 19
Study: 20723885

Group type: EXPERIMENTAL
Intervention: Unsupported online CCBT
Number of subjects: 303

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 303

Group type: COMPARATOR
Intervention: CCBT and TAU combined
Number of subjects: 303
Study: 19523672

Group type: EXPERIMENTAL
Intervention: Timothy extract monotherapy (19 microg Phl p 5 daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Timothy extract plus 9 additional pollen extracts
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17058921

Group type: EXPERIMENTAL
Intervention: Collagen application in mastoidectomy (22 cases, 22 ears)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No collagen application in mastoidectomy (19 cases, 19 ears)
Number of subjects: 41
Study: 14746626

Group type: EXPERIMENTAL
Intervention: Special silk clothes (MICROAIR DermaSilk) worn for a week
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cotton clothing (control group)
Number of subjects: 46
Study: 11700495

Group type: EXPERIMENTAL
Intervention: SCD Response System
Number of subjects: 20

Group type: COMPARATOR
Intervention: SCD Sequel System
Number of subjects: 20
Study: 9407153

Group type: EXPERIMENTAL
Intervention: Threshold of 10,000 platelets per cubic millimeter
Number of subjects: 255

Group type: COMPARATOR
Intervention: Threshold of 20,000 platelets per cubic millimeter
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 255
Study: 7517135

Group type: EXPERIMENTAL
Intervention: Woman-made erotic film
Number of subjects: 47

Group type: COMPARATOR
Intervention: Man-made erotic film
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Both films
Number of subjects: 47
Study: 3497039

Group type: EXPERIMENTAL
Intervention: 10 mg tenoxicam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg tenoxicam
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 40 mg tenoxicam
Number of subjects: 12
Study: 29962227

Group type: EXPERIMENTAL
Intervention: Balance and gait exercises (10 weeks, three times/week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 100
Study: 28274268

Group type: EXPERIMENTAL
Intervention: True acupuncture + metformin placebo
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham acupuncture + metformin
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham acupuncture + metformin placebo
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 342

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 342
Study: 26158468

Group type: EXPERIMENTAL
Intervention: Low attentional load task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High attentional load task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Appetitive solutions (juice)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aversive solutions (quinine)
Number of subjects: 0
Study: 24146762

Group type: EXPERIMENTAL
Intervention: Sirolimus (SIR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 60
Study: 20031956

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (2.5 mg per patch)
Number of subjects: 12
Study: 18400322

Group type: EXPERIMENTAL
Intervention: Group treatment program following the cognitive orientation to daily occupational performance (CO-OP) approach
Number of subjects: 43
Study: 15881046

Group type: EXPERIMENTAL
Intervention: Cognitive Orientation to daily Occupational Performance (CO‐OP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study: 12832240

Group type: EXPERIMENTAL
Intervention: Olanzapine (5-20 mg/day)
Number of subjects: 251

Group type: COMPARATOR
Intervention: Divalproex (500-2500 mg/day)
Number of subjects: 251
Study: 10830644

Group type: EXPERIMENTAL
Intervention: 2‐min open suction method
Number of subjects: 16

Group type: COMPARATOR
Intervention: 10‐min spit method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 2‐min closed suction method
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Suction machine (general preference)
Number of subjects: 16
Study: 8898260

Group type: EXPERIMENTAL
Intervention: Children with SLI
Number of subjects: 0

Group type: COMPARATOR
Intervention: Delay interval before naming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duration of prime exposure before naming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup of children with expressive but not receptive skills
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subgroup of children with both expressive and receptive language problems
Number of subjects: 0
Study: 1514669

Group type: EXPERIMENTAL
Intervention: Budesonide (800 micrograms b.d.)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (750 micrograms b.d.)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Budesonide and Beclomethasone dipropionate
Number of subjects: 36
Study: 6469823

Group type: EXPERIMENTAL
Intervention: Induced erythrocythemia (334 ml of red blood cells)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9
Study: 29974643

Group type: EXPERIMENTAL
Intervention: 595-nm pulsed dye laser (PDL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: fractional 532-nm KTP laser
Number of subjects: 20
Study: 30032504

Group type: COMPARATOR
Intervention: PEEP: 0 cmH(2)O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEP: 10 cmH(2)O
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PEEP: 15 cmH(2)O
Number of subjects: 60
Study: 26816292

Group type: EXPERIMENTAL
Intervention: Dojo (biofeedback video game)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Rayman 2: The Great Escape (control game)
Number of subjects: 138
Study: 24188509

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 301
Study: 22280502

Group type: EXPERIMENTAL
Intervention: Intermittent Preventive Treatment in infants with Sulfadoxine‐Pyrimethamine (IPTi‐SP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IPTi‐SP
Number of subjects: 0
Study: 19394499

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Sham Electroacupuncture (SEA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Advice and Exercise (A&E)
Number of subjects: 39
Study: 17443923

Group type: EXPERIMENTAL
Intervention: Reliable Change Index (RCI) with constant correction for practice effects
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Standard RCI without correction for practice
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Within-subject standard deviation (WSD) as an error estimate
Number of subjects: 160
Study: 16254575

Group type: EXPERIMENTAL
Intervention: Self-report questionnaire comprising socio‐demographic variables, dietary habits, physical activity in the home, at work and recreation
Number of subjects: 387
Study: 12030736

Group type: EXPERIMENTAL
Intervention: Formoterol 18 microg b.i.d.
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg b.i.d.
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg b.i.d. and higher
Number of subjects: 692

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Formoterol (all doses)
Number of subjects: 692
Study: 10065517

Group type: EXPERIMENTAL
Intervention: Lateral flexion-extension radiographs
Number of subjects: 36
Study: 7727666

Group type: EXPERIMENTAL
Intervention: Active laboratory‐based reporting system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive reporting system
Number of subjects: 0
Study: 2039070

Group type: EXPERIMENTAL
Intervention: Occupational rating system using job titles and an arbitrary numeric scale
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Occupational rating system using specific criteria for rating job functions
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Effective and valid rating format
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rating system developed
Number of subjects: 50
Study: 7239397

Group type: EXPERIMENTAL
Intervention: Lonazolac‐Ca
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diclofenac‐Na
Number of subjects: 20
Study: 31805985

Group type: EXPERIMENTAL
Intervention: Solar-powered oxygen (SPO2) delivery system
Number of subjects: 2400

Group type: COMPARATOR
Intervention: Standard of care oxygen delivery (without SPO2)
Number of subjects: 2400

Group type: EXPERIMENTAL
Intervention: SPO2 system functionality, safety, efficacy, operating costs, nursing knowledge, skills, and retention for oxygen administration
Number of subjects: 2400
Study: 29309483

Group type: EXPERIMENTAL
Intervention: SB-TEAM program (supervised administration of preventive asthma medication at school and 3 school-based telemedicine visits)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: SB-TEAM program
Number of subjects: 400
Study: 26926910

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) plus Treatment as Usual (TAU) - up to 12 one-hour weekly sessions.
Number of subjects: 240

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone.
Number of subjects: 240
Study: 24436135

Group type: EXPERIMENTAL
Intervention: Combination group (memantine + donepezil)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (donepezil only)
Number of subjects: 37
Study: 23202836

Group type: EXPERIMENTAL
Intervention: Lead exposure in males (6.8 ± 2.0 µg/dL)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lead exposure in females (5.9 ± 1.9 µg/dL)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Lower socioeconomic status and well water use
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Well water use
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Children with BPb concentrations of 10 µg/dL or above
Number of subjects: 108
Study: 19060628

Group type: EXPERIMENTAL
Intervention: 40 mg immediate-release fluvastatin twice daily (b.i.d.)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 80 mg extended-release fluvastatin daily
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 18090187

Group type: EXPERIMENTAL
Intervention: Premedication with diazepam 5-10 mg
Number of subjects: 760
Study: 15144039

Group type: COMPARATOR
Intervention: Influenza vaccine (group A)
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Influenza and pneumococcus vaccines simultaneously (group B)
Number of subjects: 232
Study: 11228086

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate aerosol (1.25 mg upon arrival and a second dose 15 minutes later if needed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sublingual isosorbide dinitrate (5 mg tablet)
Number of subjects: 60
Study: 9972670

Group type: EXPERIMENTAL
Intervention: 30 mg of methimazole (MMI) and 20 g of colestipol‐hydrochloride (COL) daily
Number of subjects: 92

Group type: COMPARATOR
Intervention: 30 mg of MMI daily
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 15 mg of MMI and 20 g of COL daily
Number of subjects: 92
Study: 8054260

Group type: EXPERIMENTAL
Intervention: Magnesium pidolate 4.5 g/d for one month
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 3175536

Group type: EXPERIMENTAL
Intervention: Acarbose (Bay g 5421)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1106807

Group type: EXPERIMENTAL
Intervention: Dexon (polyglycolic acid) sutures
Number of subjects: 104

Group type: COMPARATOR
Intervention: Silk sutures
Number of subjects: 104

Group type: COMPARATOR
Intervention: Polyethylene sutures
Number of subjects: 104

Group type: COMPARATOR
Intervention: Nylon sutures
Number of subjects: 104
Study: 31068018

Group type: EXPERIMENTAL
Intervention: Combined passive head-up and -down movement with device-guided slow breathing
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 14
Study: 28974570

Group type: EXPERIMENTAL
Intervention: Slow sodium (200 mmol/d)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (70 mmol sodium/d)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 48
Study: 26698878

Group type: EXPERIMENTAL
Intervention: Ibuprofen 3 × 400 mg for three days
Number of subjects: 494

Group type: COMPARATOR
Intervention: Fosfomycin 3 g (single dose) for three days
Number of subjects: 494
Study: 22886633

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 21193696

Group type: EXPERIMENTAL
Intervention: Augmented intensity postinduction intensification (PII)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Standard intensity postinduction intensification (PII)
Number of subjects: 272
Study: 18714245

Group type: EXPERIMENTAL
Intervention: Elastic Bands (EBG)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Weight Machines (WMG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study: 17201265

Group type: EXPERIMENTAL
Intervention: Xuanju compound capsule combined with erogenous focus exercise
Number of subjects: 52

Group type: COMPARATOR
Intervention: Erogenous focus exercise alone (Control)
Number of subjects: 52
Study: 12559215

Group type: COMPARATOR
Intervention: Furosemide withdrawal
Number of subjects: 29

Group type: COMPARATOR
Intervention: Continuing furosemide
Number of subjects: 29
Study: 10690863

Group type: EXPERIMENTAL
Intervention: 100 IU/day recombinant human FSH (Puregon)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: 200 IU/day recombinant human FSH (Puregon)
Number of subjects: 38
Study: 9068529

Group type: EXPERIMENTAL
Intervention: Intracoronary estradiol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 8446138

Group type: EXPERIMENTAL
Intervention: Diltiazem (120 to 360 mg per day)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Atenolol (25 to 100 mg per day)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Clonidine (0.2 to 0.6 mg per day)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (12.5 to 50 mg per day)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Captopril (25 to 100 mg per day)
Number of subjects: 1292

Group type: EXPERIMENTAL
Intervention: Prazosin (4 to 20 mg per day)
Number of subjects: 1292

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1292
Study: 3535525

Group type: EXPERIMENTAL
Intervention: Hydrogel contact lenses with lower water content (38%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrogel contact lenses with higher water content (55% and 70%)
Number of subjects: 10
Study: 29898035

Group type: EXPERIMENTAL
Intervention: Functional resistance training
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Conventional resistance training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 25792588

Group type: EXPERIMENTAL
Intervention: Gel pad application
Number of subjects: 20

Group type: COMPARATOR
Intervention: No gel pad application (control)
Number of subjects: 20
Study: 24021313

Group type: EXPERIMENTAL
Intervention: CYD‐TDV 5555
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CYD‐TDV 5553
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: CYD‐TDV 4444
Number of subjects: 260
Study: 20056931

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator (tPA)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 18633420

Group type: EXPERIMENTAL
Intervention: Motor physical therapy (15 min daily, 5 times per week until discharge)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 29
Study: 16849118

Group type: EXPERIMENTAL
Intervention: Post-dinner snack
Number of subjects: 60

Group type: COMPARATOR
Intervention: No snack
Number of subjects: 60
Study: 12770975

Group type: EXPERIMENTAL
Intervention: topical dorzolamide
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study: 10971777

Group type: EXPERIMENTAL
Intervention: Nitrous oxide anaesthesia
Number of subjects: 69

Group type: COMPARATOR
Intervention: Propofol anaesthesia
Number of subjects: 69
Study: 9601864

Group type: EXPERIMENTAL
Intervention: Spirapril 3 mg or 6 mg
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Spirapril 12 mg (small proportion of patients)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Spirapril (overall treatment)
Number of subjects: 168
Study: 8224265

Group type: EXPERIMENTAL
Intervention: Flutamide 500 mg/d
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flutamide 750 mg/d
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Flutamide 500 mg/d and 750 mg/d
Number of subjects: 18
Study: 3896278

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg three times daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29985636

Group type: EXPERIMENTAL
Intervention: Testimonial pictorial warning labels (PWLs) with an image and basic warning statement
Number of subjects: 1255

Group type: COMPARATOR
Intervention: Text only warning labels
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Testimonial PWLs with identifiers (name, age, health status)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Testimonial PWLs with explanatory statements (testimonial/non-testimonial)
Number of subjects: 1255

Group type: EXPERIMENTAL
Intervention: Basic warning statement with an image of a real person
Number of subjects: 1255
Study: 29120250

Group type: EXPERIMENTAL
Intervention: Nepafenac treatment (0.1%, three times/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 34
Study: 26642810

Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Capecitabine (2000 mg/m2 on days 1 to 14)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Vinorelbine (25 mg/m2 on days 1 and 8)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Lapatinib (1250 mg) combined with Gemcitabine (1000 mg/m2 on days 1 and 8)
Number of subjects: 142
Study: 24690511

Group type: EXPERIMENTAL
Intervention: Group-based self-management support programme (three monthly group sessions and a booster session three months later)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Single information meeting (control condition)
Number of subjects: 160
Study: 23220811

Group type: EXPERIMENTAL
Intervention: Exercise program
Number of subjects: 39

Group type: COMPARATOR
Intervention: Glucosamine sulfate (1500 mg/day) plus exercise therapy
Number of subjects: 39
Study: 20975470

Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 40

Group type: COMPARATOR
Intervention: Landmark-based technique
Number of subjects: 40